Previous Page  25 / 56 Next Page
Information
Show Menu
Previous Page 25 / 56 Next Page
Page Background

AIO-STO-0415: RAMIRIS trial

25

•

Gastric/GEJ adenocarcinoma

•

PD during or within 6m of the last dose

of 1L platinum and fluoropyrimidine

doublet with or without anthracycline

or docetaxel

•

PS0-1

N=111

https://clinicaltrials.gov/ct2/show/NCT03081143?term=RAMIRIS&rank=1

FOLFIRI

+

Ramucirumab

28-day cycle

Paclitaxel

+

Ramucirumab

28-day cycle

Primary endpoint

•

OS at 6 months

Secondary endpoints

•

PFS

•

ORR

•

DCR

•

Safety

•

QOL

PI: Sylvie Lorenzen, MD

Trial contact person: Salah-Eddin Al-Batran, Prof